Novavax revenue plunges 79% as company pivots to licensing-led model

Novavax (NASDAQ:NVAX) reported a significant contraction in top-line results for the first quarter of 2026, reflecting the company’s ongoing transition from a high-volume manufacturer to a leaner, research-and-licensing-focused biotechnology entity.

The Gaithersburg, Maryland-based firm posted total revenue of $140 million for the quarter ended March 31, 2026, a 79% decrease compared to the $667 million reported in the same period last year.

The revenue mix shifted heavily toward intellectual property monetization.

Licensing, royalties, and other revenue accounted for $97 million of the quarterly total.

This figure was bolstered by a $30 million upfront payment from Pfizer, part of a broader strategic agreement to utilize Novavax’s proprietary technology.

Despite the substantial drop in sales, Novavax reported a narrowed net loss of $9 million, as aggressive cost-reduction measures and a reduced manufacturing footprint began to stabilize the bottom line.

Financial stability remains a priority for management as it navigates a post-pandemic vaccine market.

Novavax ended the quarter with $795 million in cash and cash equivalents.

Furthermore, the company strengthened its liquidity position by closing a new $330 million credit facility, providing additional runway for its pipeline development, including its combined COVID-19 and influenza vaccine candidates.